This 2025 Epitalon paper studied human-derived cell lines, including cancer and non-cancer cell systems. It did not test whether people lived longer. A later figure correction is part of the publication record and must remain attached to any appraisal. Primary study, publisher correction
What the authors reported
The authors measured telomere-related responses, including hTERT expression, telomerase activity, and alternative lengthening of telomeres, abbreviated ALT. They reported different patterns in normal and cancer-cell systems, including ALT-associated changes in cancer cells. These are cell-model findings, not established clinical anti-aging effects. Primary study
The correction must be checked
The publisher's November 15, 2025 correction states that incorrect figures had appeared as Figures 1, 2, and 3 and that the original article was corrected. A reader should consult the corrected version and the notice together rather than relying on an earlier screenshot or downloaded copy. The notice does not, by itself, establish misconduct. Publisher correction
Why a biomarker change is not a longevity result
Our interpretation preserves the distinction between a measurement within cells and a whole-person outcome. Even if an experimental biomarker change is reproduced, its relevance to benefit, harm, and long-term function requires separate evidence. Describing a marker as associated with aging does not make every intervention that changes it beneficial.
For an original thought experiment, imagine a laboratory measure changes in two cell types through different pathways. One summary calls both changes “rejuvenation”; another records the pathways and leaves clinical meaning unresolved. The second preserves information that the first removes. This matters particularly when normal and cancer-cell models appear in the same paper.
A version-aware reading checklist
| Check | Record |
|---|---|
| Article version | Which corrected text and figures were inspected? |
| Cell model | Which result belongs to which cell system? |
| Assay | What was measured directly? |
| Interpretation | What remains a proposed implication rather than a measured outcome? |
Frequently asked questions
Was this a human longevity trial?
No. Human-derived cells do not constitute enrolled human participants.
Did the paper have a correction?
Yes. The publisher corrected Figures 1–3.
Does a correction automatically invalidate every result?
No. Its scope must be assessed against the corrected record.
Does the correction prove misconduct?
No such conclusion is established by the notice cited here.
Did the cell types show identical mechanisms?
The authors reported differing telomere-related patterns across the systems.
Does longer telomere length establish safety?
No. It is not a comprehensive safety endpoint.
What is still required for final review?
Inspect the corrected figures and full methods, verify numerical claims and disclosures, and check for subsequent notices. This draft currently relies on the primary abstract and correction text.